RGEN (Repligen) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 12, 2026)


RGEN Repligen Corp RGEN
84 GF Score
Price $144.24
GF Value $176.77
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen 5-Year Yield-on-Cost %?

Repligen RGEN +0.20% 84 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.77 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Repligen ranks worse than 305810.09% on this metric.

Repligen's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Repligen's 5-Year Yield-on-Cost % or its related term are showing as below:



RGEN's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.34
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Repligen  (NAS:RGEN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Repligen 5-Year Yield-on-Cost % Related Terms


RGEN vs ATR, AVTR, TFX: 5-Year Yield-on-Cost % Comparison

For the Medical Instruments & Supplies subindustry, Repligen's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Repligen's 5-Year Yield-on-Cost % falls into.


RGEN
84GF Score
Repligen Corp RGEN
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Repligen is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Repligen (RGEN) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Repligen and its competitors. According to the industry distribution chart, Repligen ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Repligen's 5-Year Yield-on-Cost % too high?
Repligen's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Repligen ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's 5-Year Yield-on-Cost % compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Repligen in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.77, compared to a current price of $144.24 — trading 18.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Repligen (RGEN), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $144.24 is trading 18.4% below its estimated GF Value™ of $176.77. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $176.77 vs. price of $144.24 (18.4% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$144.24
Price
$176.77
GF Value